Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for Lactation Inhibition (eLISTA)
NCT06029673Phase 2Completed
- Sponsor
- Stanford University
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabergoline in breast engorgement, mastalgia, sponsored by Stanford University. Started Feb 2024; status: completed.
02
Drugs
cabergoline
03
Conditions
breast engorgementmastalgia
Beyond the preview
Go deeper on NCT06029673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029673.